PROFILPELAJAR.COM

Molnupirabir

Molnupirabir
Formula kimikoaC13H19N3O7
SMILES kanonikoa2D eredua
SMILES isomerikoa
CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)NO)O)O
MolView3D eredua
Konposizioakarbono, Nitrogeno, oxigeno eta hidrogeno
EponimoaMjölnir
Motakonposatu kimiko
Masa molekularra329,122299948 Da
Erabilera
Konposatu aktiboaLagevrio (en) Itzuli
Rolaantiviral agent (en) Itzuli
Identifikatzaileak
InChlKeyHTNPEHXGEKVIHG-QCNRFFRDSA-N
CAS zenbakia2349386-89-4
ChemSpider84400552
PubChem145996610
Gmelin180653
EC zenbakia859-180-1
ECHA100.310.497
UNIIYA84KI1VEW
PDB LigandXMO

Molnupirabirra konposatu organikoa da C13H19N3O7 formula duena. Nukleosioden analogoa da[1].

Molnupirabirra, Lagevrio markarrekin saltzen da botika antibiral gisa, hainbat RNA birusek beren burua errepikatzea eragozten duelako. Gripea tratatzeko botika gisa sintetizatu zen lehen aldiz 2018an eta gerora COVID-19a tratatzeko usatu da hainbat herrialdetan (AEBtan eta Erresuma Batuan etsenplurako) SARS-CoV-2-z kutsatutakoak tratatzeko[2][3].

Europar Batasunean ez du baimenik erabilia izateko. 2021an Sendagaien Europako Agentziak azterketa bat abiatu zuen Molnupirabirraren erabilera pediatrikoari buruz, 2023an eten zuena emaitza egokirik eman ez zuelako[4].

Molnupirabirra profarmako bat da N4-hidroxizitidina nukleosido deribatu sintetikoarena. RNAren errepikatze-prozesuan akatsa sortuaz egiten du lan[5].

Sintesia

Molnupirabirra uridina lehengai gisa usatuz sintetizatzen da[6].

Synthesis of molnupiravir from uridine

Erreferentziak

  1. ↑ (Ingelesez) PubChem. «Molnupiravir» pubchem.ncbi.nlm.nih.gov (kontsulta data: 2024-12-30).
  2. ↑ Summary of Product Characteristics for Lagevrio. Gob.UK.
  3. ↑ (Ingelesez) Commissioner, Office of the. (2024-08-09). «Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults» FDA (kontsulta data: 2024-12-30).
  4. ↑ Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision. European Medicines Agency.
  5. ↑ Toots, Mart; Yoon, Jeong-Joong; Cox, Robert M.; Hart, Michael; Sticher, Zachary M.; Makhsous, Negar; Plesker, Roland; Barrena, Alec H. et al.. (2019-10-23). «Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia» Science Translational Medicine 11 (515): eaax5866.  doi:10.1126/scitranslmed.aax5866. PMID 31645453. PMC PMC6848974. (kontsulta data: 2024-12-30).
  6. ↑ (Ingelesez) Painter, George R.; BLUEMLING, Gregory R.; Natchus, Michael G.; Guthrie, David. (2020-09-03). N4-hydroxycytidine and derivatives and anti-viral uses related thereto. (kontsulta data: 2024-12-30).

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.